Drug Profile
Galantamine - Janssen/Sanochemia Pharmazeutika
Alternative Names: Galantamine Hydrobromide; Galanthamine; GP 37267; Nivalin; R-113675; Razadyne; Razadyne ER; Reminyl; Reminyl ERLatest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator Sanochemia Pharmazeutika
- Developer Janssen Pharmaceutical KK; Janssen-Cilag; Sanochemia Pharmazeutika
- Class Alkaloids; Benzazepines; Nootropics; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alzheimer's disease
- Discontinued Chronic fatigue syndrome; Delirium; Down syndrome; Fibromyalgia; Mild cognitive impairment; Vascular dementia
Most Recent Events
- 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
- 08 Apr 2021 Discontinued - Phase-I/II for Down syndrome (In adolescents, In children) in Belgium (PO) (EudraCT2006-003359-19)
- 08 Apr 2021 Discontinued - Phase-I/II for Down syndrome (In adolescents, In children) in Netherlands (PO) (EudraCT2006-003359-19)